What’s Going On With the Wegovy Shortages?
Some of Novo Nordisk’s popular weight loss drug Wegovy is back in stock in the U.S. after months of limited supplies, according to an update on the Food and Drug Administration’s website, though shortages are set to continue as booming demand for obesity drugs still vastly outstrips Big Pharma’s ability to ramp up production.
Eli Lilly’s Zepbound is the only other GLP-1 medication on the U.S. market for weight loss. Like Novo’s Wegovy, demand is high and supplies are limited. Of the six Zepbound injector doses listed on the FDA’s database, only the smallest, 2.5 milligrams, is “available.” The other doses — 5 milligram, 7.5 milligram, 10 milligram, 12.5 milligram and 15 milligram — are all listed as “limited availability” due to increased demand. Doses of Mounjaro, Lilly’s injectable diabetes drug containing the same drug as Zepbound, tirzepatide, are also in short supply. As with Zepbound, six doses (with the same values as Zepbound) are on the market and only the lowest 2.5 milligram dose is “available.” The FDA estimates shortages for both Mounjaro and Zepbound will persist through the first half of 2024.
Excerpted from Forbes
